TIDMEKF

RNS Number : 0981O

EKF Diagnostics Holdings PLC

05 October 2021

EKF Diagnostics Holdings plc

("EKF" or the "Company")

PDMR/ PCA Dealings

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that the Board of EKF has been informed that on Friday 1 October, 2021, certain funds connected to Christopher Mills, Non-executive Chairman, sold a total of 1,275,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 84.0 pence per Ordinary Share.

Following this transaction, Christopher Mills' total direct and indirect interest in the Company is 130,875,000 Ordinary Shares, representing approximately 28.76% of the total voting rights over the Company's issued share capital.

The Notification of Dealing Form required in accordance with UK MAR is set out below and reflects the sale of 637,500 Ordinary Shares by each of the North Atlantic Smaller Companies Investment Trust plc ("NASCIT") and the Oryx International Growth Fund Limited ("Oryx").

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                     Christopher Mills 
      ---------------------------------------  -------------------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------------------------- 
 a)    Position/status                          Christopher Mills is Non-executive 
                                                 Chairman of the Company. 
 
                                                 Mr. Mills is a partner and Chief 
                                                 Investment Officer of Harwood Capital 
                                                 LLP. Harwood Capital LLP is Investment 
                                                 Manager to NASCIT. 
 
                                                 Mr Mills is also a director of Harwood 
                                                 Capital Management (Gibraltar) Limited, 
                                                 which is Investment Manager and Investment 
                                                 Adviser to Oryx. 
      ---------------------------------------  -------------------------------------------------- 
 b)    Initial notification                     Initial Notification 
        /Amendment 
      ---------------------------------------  -------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------------- 
 a)    Name                                     EKF Diagnostics Holdings plc 
      ---------------------------------------  -------------------------------------------------- 
 b)    LEI                                      213800DXTF3EAUK1AR05 
      ---------------------------------------  -------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------------------- 
 a)    Description of the                       Ordinary shares of GBP0.01 each 
        financial instrument, 
        type of instrument 
 
       Identification code                      GB0031509804 
 
 b)    Nature of the transaction                Sale of shares 
      ---------------------------------------  -------------------------------------------------- 
 c)    Price(s) and volume(s) 
                                                -----------------------  ---------------------- 
                                                 Price(s)                 Volume(s) 
                                                -----------------------  ---------------------- 
    GBP0.84                                                               637,500 
   --------------------------------------------------------------------  ---------------------- 
    GBP0.84                                                               637,500 
   --------------------------------------------------------------------  ---------------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                      1,275,000 
 
  - Price                                  GBP0.84 
 
 e)    Date of the transaction                  1 October 2021 
      ---------------------------------------  -------------------------------------------------- 
 f)    Place of the transaction                 London Stock Exchange 
      ---------------------------------------  -------------------------------------------------- 
 
 
EKF Diagnostics Holdings plc                                      www.ekfdiagnostics.com 
Christopher Mills, Non-executive Chairman                       Tel: +44 (0)29 2071 0570 
Mike Salter, CEO 
Richard Evans, FD & COO 
 
Singer Capital Markets (Nominated Adviser & Joint              Tel: +44 ( 0)20 7496 3000 
 Broker) 
Aubrey Powell / George Tzimas / Tom 
 Salvesen 
 
Investec Bank plc (Joint Broker)                                Tel: +44 (0)20 7597 4000 
Gary Clarence / Daniel Adams 
 
Walbrook PR Limited                       Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Cawthorne               Mob: +44 (0)7980 541 893 / +44 (0)7584 391 
                                                                                     303 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUPGCCUUPGGWA

(END) Dow Jones Newswires

October 05, 2021 10:00 ET (14:00 GMT)

Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Ekf Diagnostics.
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Ekf Diagnostics.